ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

ClinicalTrials.gov ID: NCT07281417

Public ClinicalTrials.gov record NCT07281417. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Neoadjuvant Chemotherapy With or Without Cemiplimab (REGN2810) in Sinonasal Squamous Cell Carcinoma: A Randomized Phase 2 Study

Study identification

NCT ID
NCT07281417
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
National Cancer Institute (NCI)
NIH
Enrollment
108 participants

Conditions and interventions

Interventions

  • Biopsy Procedure Procedure
  • Biospecimen Collection Procedure
  • Carboplatin Drug
  • Cemiplimab Biological
  • Chemoradiotherapy Other
  • Cisplatin Drug
  • Computed Tomography Procedure
  • Magnetic Resonance Imaging Procedure
  • Paclitaxel Drug
  • Positron Emission Tomography Procedure
  • Radiation Therapy Radiation
  • Surgical Procedure Procedure

Procedure · Drug · Biological + 2 more

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 23, 2026
Primary completion
Dec 15, 2030
Completion
Dec 15, 2030
Last update posted
May 4, 2026

2026 – 2030

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
University of Kentucky/Markey Cancer Center Lexington Kentucky 40536 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07281417, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 4, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07281417 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →